<DOC>
	<DOCNO>NCT01204437</DOCNO>
	<brief_summary>Although approximately 50 % new diagnosis breast cancer patient age 65 , elderly people remain substantially under-represented clinical trial , therefore under-treated . A recent trial CALBG patient 's ≥ 65 year medium risk breast cancer demonstrate improved disease-free overall survival treat AC CMF compare treated capecitabine alone . The primary aim ICE II trial determine compliance toxicity epirubicin plus cyclophosphamide ( EC ) CMF versus nab-paclitaxel plus capecitabine adjuvant therapy non frail elderly patient .</brief_summary>
	<brief_title>Adjuvant Chemotherapy Elderly Non Frail Patients With Increased Risk Relapse Primary Carcinoma Breast</brief_title>
	<detailed_description>Primary Objective : Phase II : To determine compliance safety epirubicin plus cyclophosphamide CMF ( EC/CMF ) nab-paclitaxel combination capecitabine ( PX ) . Secondary Objective ( ) : 1 . To compare disease-free survival ( DFS ) distant disease free survival ( DDFS ) epirubicin plus cyclophosphamide CMF ( EC/CMF ) vs. nab-paclitaxel combination capecitabine ( PX ) . 2 . To compare overall survival ( OS ) epirubicin plus cyclophosphamide CMF ( EC/CMF ) vs nab-paclitaxel combination capecitabine ( PX ) . 3 . To analyze efficacy treatment subgroups accord clinical stratification factor . 4 . To determine prognostic factor tumor tissue collect primary surgery correlate study treatment effect . 5 . To compare geriatric assessment score ( Charlson , VES-13 , IADL , G8 ) baseline end therapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Written inform consent study procedure must obtain document accord local regulatory requirement prior begin specific protocol procedure . 2 . Complete baseline documentation must send GBG Forschungs GmbH . 3 . Histological confirm unilateral bilateral primary carcinoma breast . 4 . Female male breast cancer patient age first histologically diagnosis axilla dissection ≥ 65 year . 5 . Adequate surgical treatment complete resection ( R0 ) tumor ≥ 10 axillary node . Sole sentinel node biopsy allow sentinel node show tumor involvement . 6 . No evidence distant metastasis bone scan , liver ultrasound chest xray . 7 . Patients stage pT3/4 pN2/3 ( ≥ 4 involved lymph node ) irrespective additional risk factor . 8 . Patients stage pT1/2 pN0/1 ( 03 involve lymph node ) increase risk accord clinicopathological uPA/PAI1 criterion . 9 . ECOG Performance Status &lt; = 2 . 10 . Charlson Scale &lt; = 2 . 11 . Estimated life expectancy least 5 year ( irrespective breast cancer diagnosis ) . 12 . The patient must accessible treatment followup . Patients register trial must treat follow participate centre could Principal Co investigator 's site . 1 . Known hypersensitivity reaction compound incorporated substance know dihydropyrimidine dehydrogenase deficiency . 2 . Low risk patient accord risk assessment . 3 . Inadequate organ function include : Leucocytes &lt; 3,5 G/l , Platelets &lt; 100 G/l , Creatinine Bilirubin normal limit ( 1,25 upper normal limit ) , CreatinineClearance 50 ml/min , uncompensated cardiac function , severe relevant comorbidity would interact application cytotoxic agent participation study . 4 . Previously currently one follow medical condition : preexisting motor sensory neuropathy severity &gt; = grade 2 NCICTC criterion ; history significant neurological psychiatric disorder include psychotic disorder , dementia seizure would prohibit understanding give informed consent ; know suspect congestive heart failure ( &gt; NYHA I ) and/or coronary heart disease , angina pectoris require antianginal medication , previous history myocardial infarction , evidence transmural infarction ECG , un poorly control arterial hypertension ( i.e . BP &gt; 150/100 mmHg treatment two antihypertensive drug ) , rhythm abnormality require permanent treatment , clinically significant valvular heart disease ; Creatinine Clearance less 50 ml/min ; another primary malignancy eventfree survival &lt; 5 year , except curatively treat basalioma skin carcinoma situ cervix . 5 . Time since axillary dissection &gt; 3 month . 6 . Locally advanced , nonoperable breast cancer . 7 . Previous invasive breast carcinoma . 8 . Prior chemotherapy malignancy . 9 . Concurrent specific systemic antitumor treatment treatment experimental compound within last 6 month . 10 . Concurrent treatment tumor specific experimental drug . Participation another clinical trial investigational market drug . 11 . Concurrent treatment virostatic agent like sorivudine analogue like brivudine , concurrent treatment aminoglycosides , anticoagulant : heparin , warfarin well acetylic acid ( e.g . Aspirin® ) dose &gt; 325mg/day clopidogrel dose &gt; 75 mg/day ) .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>primary carcinoma</keyword>
	<keyword>elderly non frail patient</keyword>
	<keyword>EC</keyword>
	<keyword>CMF</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Nab-Paclitaxel</keyword>
</DOC>